Filtered By:
Condition: Ischemic Stroke
Countries: Canada Health
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 362 results found since Jan 2013.
COVID-19 and the Cardiovascular System: Insights into Effects and Treatments
Can J Physiol Pharmacol. 2021 Sep 21. doi: 10.1139/cjpp-2021-0093. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19), an acute and highly transmissible infectious disease has reached a pandemic level since March 11, 2020 and continues to challenge the healthcare system worldwide. The pathogenesis of COVID-19 is a complex process involving mechanisms that suppress the host antiviral and innate immune response, while triggering marked activation of coagulation and hyperinflammation leading to cytokine storm in severe COVID-19. This review summarizes current evidence related to COVID-19-associated cardiovascul...
Source: Canadian Journal of Physiology and Pharmacology - September 21, 2021 Category: Drugs & Pharmacology Authors: Joey-Bahige Chammas Dylan Delaney Naim Chabaytah Sarah Abdulkarim Adel Schwertani Source Type: research
Neuroprotection in Acute Ischaemic Stroke: A Brief Review
Can J Neurol Sci. 2021 Sep 16:1-16. doi: 10.1017/cjn.2021.223. Online ahead of print.NO ABSTRACTPMID:34526172 | DOI:10.1017/cjn.2021.223
Source: The Canadian Journal of Neurological Sciences - September 16, 2021 Category: Neurology Authors: Alastair M Buchan David M Pelz Source Type: research
E-011 Factors influencing thrombectomy decision-making for primary medium vessel occlusion stroke
ConclusionsMost physicians in this survey would treat MeVO stroke patients immediately with EVT, supporting the need for more robust clinical evidence.Disclosures P. Cimflova: None. M. Kappelhof: None. N. Singh: None. N. Kashani: None. J. Ospel: None. R. McDonough: None. A. Demchuk: None. B. Menon: None. N. Sakai: None. M. Chen: 2; C; Medtronic, Genentech, Stryker, Microvention, Cerenovus, Penumbra. J. Fiehler: 1; C; Acandis, Medtronic, Microvention, Stryker. 2; C; Acandis, Codman, Cerenovus, Microvention, Medtronic, Penumbra, Phenox, Stryker. M. Goyal: 2; C; Medtronic, Microvention, Stryker, GE Healthcare, Mentice.
Source: Journal of NeuroInterventional Surgery - July 26, 2021 Category: Neurosurgery Authors: Cimflova, P., Kappelhof, M., Singh, N., Kashani, N., Ospel, J., McDonough, R., Demchuk, A., Menon, B., Sakai, N., Chen, M., Fiehler, J., Goyal, M. Tags: Electronic poster abstracts Source Type: research
Choice of Time-Scale in Time-to-Event Analysis: Evaluating Age-Dependent Associations
CONCLUSIONS: When evaluating age-dependent association between an exposure and outcome, estimates of association vary based on the time-scale used in survival analysis, requiring thoughtful consideration.PMID:34174410 | DOI:10.1016/j.annepidem.2021.06.006
Source: Annals of Epidemiology - June 26, 2021 Category: Epidemiology Authors: Manav V Vyas Jiming Fang Moira K Kapral Peter C Austin Source Type: research
Improved detection of atrial fibrillation could prevent disabling strokes
(University of Alberta Faculty of Medicine& Dentistry) A clinical trial examining the efficacy of two devices to monitor and detect atrial fibrillation (AF), or an irregular heartbeat, in ischemic stroke patients -- one an implantable device that monitors over 12 months, the other an external device that monitors over a 30-day period -- found the implantable device is more than three times more effective in detecting AF, and both are a significant improvement over the current standard of care in Alberta, Canada.
Source: EurekAlert! - Medicine and Health - June 1, 2021 Category: International Medicine & Public Health Source Type: news
Dose Specific Effectiveness and Safety of DOACs in Patients with Non-valvular Atrial Fibrillation: a Canadian Retrospective Cohort Study
Direct oral anticoagulants (DOACs) have been proven to be effective and safe for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). However, suboptimal adherence, variable dosing and use in patient populations that otherwise would have been excluded from clinical trials may impact the efficacy and safety profile of DOACs in a routine care setting. We compared stroke, bleeding, and mortality rates on and off therapy for standard and low-dose DOACs (apixaban, rivaroxaban, dabigatran) versus warfarin in a Canadian cohort.
Source: Thrombosis Research - May 10, 2021 Category: Hematology Authors: Elham Rahme, Richard Godin, Hacene Nedjar, Kaberi Dasgupta, Vicky Tagalakis Source Type: research
Trends in Anticoagulant Use at Nursing Home Admission and Variation by Frailty and Chronic Kidney Disease Among Older Adults with Atrial Fibrillation
ConclusionsWhile the proportion of residents with AF receiving oral anticoagulants at admission increased following the approval of DOACs, over 40% remained untreated. Among those treated, use of a DOAC increased, while warfarin use declined. The impact of these recent treatment patterns on the balance between benefit and harm among residents warrant further investigation.
Source: Drugs and Aging - April 21, 2021 Category: Geriatrics Source Type: research
Disability assessment in acute ischemic stroke: Which score/instrument is better?
Can J Neurol Sci. 2021 Apr 5:1-5. doi: 10.1017/cjn.2021.60. Online ahead of print.NO ABSTRACTPMID:33818331 | DOI:10.1017/cjn.2021.60
Source: The Canadian Journal of Neurological Sciences - April 5, 2021 Category: Neurology Authors: Prateek Kumar Panda Indar Kumar Sharawat Source Type: research
